New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 19, 2014
09:47 EDTLCILannett could see decreased digoxin sales, says Craig-Hallum
Last week an article in the Journal of American College of Cardiology, or JACC, highlighted concerns regarding increased mortality for Digoxin users. Craig-Hallum said Digoxin is one of Lannett's top drugs and believes the study combined with the push-back on last year's price increase could lead to a decrease in Digoxin sales. Shares are Buy rated but the analyst is growing more cautions near-term.
News For LCI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 27, 2015
06:57 EDTLCILannett completes acquisition of Kremers Urban for roughly $1.23B
Lannett Company (LCI) announced that it has completed the acquisition of Kremers Urban Pharmaceuticals, the U.S. specialty generic pharmaceuticals subsidiary of global biopharmaceuticals company UCB S.A. (UCBJY). Lannett has acquired KU from UCB for total consideration of approximately $1.23B, subject to certain adjustments, including a customary working capital adjustment, a deduction of certain reimbursable amounts payable in connection with the financing of the transaction, and a reduction for any indebtedness and unpaid transaction expenses of KU existing at closing. In connection with the transaction, Lannett issued to UCB $200M senior unsecured notes along with 2.5M warrants, which may be net settled. UCB will also be eligible to receive contingent payments for Methylphenidate HCI ER when the product's AB rating is restored. The combined company generated pro-forma revenues of more than $800M for the 12 months ended June 30, 2015. KU brings a diversified commercial product portfolio of 18 products; a strong pipeline that includes 11 product applications pending at the FDA.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use